Trial Profile
A Multi-Center, Open Label, Single Arm, Multiple Dose Study to Assess the Pharmacokinetics of RO5072759 in Chinese Patients With CD20+ Malignant Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Obinutuzumab (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Pharmacokinetics
- Acronyms GERSHWIN
- Sponsors Roche
- 10 Jan 2017 Results published in the British Journal of Clinical Pharmacology.
- 29 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.